4D pharma Presents Late-Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
Open Orphan (ORPH), a specialist contract research organisation said it noted market speculation regarding a potential delisting. The company confirmed that it has no plans to delist and is working
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Boston, Drumz, Empire, Genedrive, Keras, Live,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Deltex, Empire, Galileo, Induction, Kefi, Live,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Arrow Exploration Corp, Alkemy, Argos, Arc,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Avacta, Agronomics, COPL, Cobra, Empire, FireAngel,
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
Zak Mir takes a charting look at some of the most followed small caps on the London market. Today’s selection includes Arrow Exploration, Aura, Bidstack, Cyan, Diurnal, Eco, Galantas, Goldstone,
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
